Cargando…

Recent Advances in PROTACs for Drug Targeted Protein Research

Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically, PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and the specific ligand of E3 ubiquitin ligase, respectively, via a suitable linker. PROTAC degradation of the target protein is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Tingting, Xiao, Heng, Wang, Hong, Xu, Xiaowei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499226/ https://www.ncbi.nlm.nih.gov/pubmed/36142231 http://dx.doi.org/10.3390/ijms231810328

Ejemplares similares

Recent Advances of Degradation Technologies Based on PROTAC Mechanism
por: Xiao, Mingchao, et al.
Publicado: (2022)

Recent Advances in PROTAC-Based Antiviral Strategies
por: Ahmad, Haleema, et al.
Publicado: (2023)

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
por: Alabi, Shanique B., et al.
Publicado: (2021)

PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022)

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
por: Sincere, Nuwayo Ishimwe, et al.
Publicado: (2023)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
por: Wang, Chao, et al.
Publicado: (2022)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
por: Ishikawa, Minoru, et al.
Publicado: (2020)

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges
por: Wang, Chao, et al.
Publicado: (2022)

PROTAC targeted protein degraders: the past is prologue
por: Békés, Miklós, et al.
Publicado: (2022)

Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
por: Wang, Huifang, et al.
Publicado: (2023)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
por: Jin, Jinmei, et al.
Publicado: (2020)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
por: Kelm, Jeremy M., et al.
Publicado: (2023)

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG
por: Shao, Jingwei, et al.
Publicado: (2021)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
por: An, Sainan, et al.
Publicado: (2018)

The Future of Medicinal Chemistry, PROTAC, and Undruggable Drug Targets
por: Poso, Antti
Publicado: (2021)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

An overview of PROTACs: a promising drug discovery paradigm
por: Liu, Zi, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Recent Advances about the Applications of Click Reaction in Chemical Proteomics
por: Yao, Tingting, et al.
Publicado: (2021)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
por: Mancarella, Caterina, et al.
Publicado: (2023)

BacPROTACs mediate targeted protein degradation in bacteria
por: Morreale, Francesca E., et al.
Publicado: (2022)

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
por: Qi, Si-Min, et al.
Publicado: (2021)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

PROTACs: A novel strategy for cancer drug discovery and development
por: Han, Xin, et al.
Publicado: (2023)

MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
por: Vicente, André T. S., et al.
Publicado: (2022)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
por: Kim, Hanbyeol, et al.
Publicado: (2022)

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
por: Xie, Xin, et al.
Publicado: (2023)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

PROTACs in the Management of Prostate Cancer
por: Yedla, Poornachandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0e64rq0t16vafdvkceqljndurp